A book, by Gwen Olsen, the Rx reformer on a mission
Gwen Olsen spent fifteen years as a very successful sales rep in the pharmaceutical industry working for health care giants including Johnson & Johnson, Syntex Labs, Bristol-Myers Squibb, Abbott Laboratories and Forest Laboratories. Gwen now travels around the United States speaking to groups as her new work is dedicated to the memory of her niece and her mission is to stop the over-medication of our children. Rigorously researched and documented, Confessions of an Rx Drug Pusher is a moving human drama that shares one woman’s unforgettable journey of faith, forgiveness, and healing.
In the fantastic post “Mechanisms of Invisibility : forgotten Sentinels of Diethylsbestrol Progeny” on OSI Bouaké – a bi-lingual website focusing mainly on the fight against HIV/AIDS in Africa – the following points are covered in detail:
Diethylstilbestrol was one of the first identified endocrine disruptors. However, efforts to warn french physicians about the drug’s potentially dangerous effects on pregnant women failed. Emmanuelle Fillion and Didier Torny show how sentinels sometimes don’t work
A non-existent sentinel group : DES-exposed progeny
Useless sentinels or how to avoid publicizing DES knowledge
A singular history or how endocrine disruptors did not transform DES
High Bioavailability of Bisphenol A from Sublingual Exposure
A new experiment with dogs finds that Bisphenol-A (BPA) can be absorbed in the mouth and pass directly into the bloodstream, just as nitroglycerin under the tongue. This way it bypasses detoxification in the liver after absorption in the gut. The result is that much more biologically active BPA is available to possibly cause health effects, with major implications for how much risk BPA may pose for human health.
2013 Study Abstract
Bisphenol A (BPA) risk assessment is currently hindered by the rejection of reported higher than expected BPA plasma concentrations in humans after oral ingestion. These are deemed incompatible with the almost complete hepatic first-pass metabolism of BPA into its inactive glucurono-conjugated form, BPA glucuronide (BPAG).
Using dogs as a valid model, plasma concentrations of BPA were compared over a 24-h period after intravenous, orogastric and sublingual administrations, in order to establish the absolute bioavailability of BPA administered sublingually and to compare it with oral bioavailability. Methods: Six dogs were sublingually administered with BPA at 0.05 mg/kg and 5mg/kg. The time course of plasma BPA concentrations was compared with that obtained in the same dogs after intravenous administration of the same BPA doses and after a 20mg/kg BPA dose administrated by orogastric gavage.
The data indicated that the systemic bioavailability of BPA deposited sublingually was high (70-90%) and that BPA transmucosal absorption from the oral cavity led to much higher BPA internal exposure than obtained for BPA absorption from the gastro-intestinal tract. The concentration ratio of BPAG to BPA in plasma was approximately 100-fold lower following sublingual administration than after oral dosing enabling the two pathways of absorption to be easily distinguished.
These findings demonstrate that BPA can be efficiently and very rapidly absorbed through the oral mucosa by the sublingual route. This efficient systemic entry route of BPA may lead to far higher BPA internal exposures than known for BPA absorption from the gastrointestinal tract.
Many women have to take medicines while pregnant. But could they be risking the health of their unborn child? Decades after the Thalidomide scandal shocked the world, Panorama reveals how another medicine has damaged far more children. Drugs cannot be tested on pregnant women for ethical reasons, so doctors do not know if most prescription drugs are safe for the unborn child, and the system set up to monitor side-effects appears to be flawed. As evidence emerges that some common antidepressants are linked to heart defects in babies, the programme asks how much we really know about the safety of medicines women take while pregnant.
Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies
Breast cancer is one of the most common cancers and the leading cause of cancer death among women in the world.
The prevention of breast cancer continues to be an important public health issue for researchers, especially with regard to the investigation of relations between breast cancer, diet, and lifestyle.
Researchers in China analyzed the results of 26 international studies involving almost 900,000 women, including 20,000 who had breast cancer. Researchers found that those women who had the consumed the highest levels of omega-3 fatty acids from fish were 14% less likely to have breast cancer, compared with those who ate the least.
Each 0.1 g/day or 0.1% energy/day increment of intake was associated with a 5% reduction in risk.
To investigate the association between intake of fish and n-3 polyunsaturated fatty acids (n-3 PUFA) and the risk of breast cancer and to evaluate the potential dose-response relation.
Meta-analysis and systematic review of prospective cohort studies.
PubMed and Embase up to December 2012 and references of retrieved relevant articles.
Eligibility criteria for selecting studies
Prospective cohort studies with relative risk and 95% confidence intervals for breast cancer according to fish intake, n-3 PUFA intake, or tissue biomarkers.
Twenty six publications, including 20 905 cases of breast cancer and 883 585 participants from 21 independent prospective cohort studies were eligible. Eleven articles (13 323 breast cancer events and 687 770 participants) investigated fish intake, 17 articles investigated marine n-3 PUFA (16 178 breast cancer events and 527 392 participants), and 12 articles investigated alpha linolenic acid (14 284 breast cancer events and 405 592 participants). Marine n-3 PUFA was associated with 14% reduction of risk of breast cancer (relative risk for highest v lowest category 0.86 (95% confidence interval 0.78 to 0.94), I2=54), and the relative risk remained similar whether marine n-3 PUFA was measured as dietary intake (0.85, 0.76 to 0.96, I2=67%) or as tissue biomarkers (0.86, 0.71 to 1.03, I2=8%). Subgroup analyses also indicated that the inverse association between marine n-3 PUFA and risk was more evident in studies that did not adjust for body mass index (BMI) (0.74, 0.64 to 0.86, I2=0) than in studies that did adjust for BMI (0.90, 0.80 to 1.01, I2=63.2%). Dose-response analysis indicated that risk of breast cancer was reduced by 5% per 0.1g/day (0.95, 0.90 to 1.00, I2=52%) or 0.1% energy/day (0.95, 0.90 to 1.00, I2=79%) increment of dietary marine n-3 PUFA intake. No significant association was observed for fish intake or exposure to alpha linolenic acid.
Higher consumption of dietary marine n-3 PUFA is associated with a lower risk of breast cancer. The associations of fish and alpha linolenic acid intake with risk warrant further investigation of prospective cohort studies. These findings could have public health implications with regard to prevention of breast cancer through dietary and lifestyle interventions.
Should genetically modified human embryos be allowed?
Following the news that the controversial fertility treatment developed in the UK Newcastle University – which could eradicate incurable inherited diseases – had the public’s backing, UK chief medical officer, Professor Dame Sally Davies, has announced that draft regulations will be published within months. Professor Dame Sally Davies predicts that couples affected by mitochondrial disease could benefit from the treatment within two years, enabling them to have healthy children.
De wetenschappelijke adviescommissie van het DES Centrum heeft hard gewerkt aan de evaluatie en herziening van het screeningsprotocol voor DES-dochters.
Nu is er ook een ‘vertaling’ van het screeningsprotocol beschikbaar voor de DES-dochters zelf.
” Het DES Centrum adviseert DES-dochters al jaren om regelmatig een uitstrijkje te laten maken. Per 2012 is door de wetenschappelijke adviescommissie van het DES Centrum een nieuw advies opgesteld. Dit is voorgelegd aan de Werkgroep Cervix Uteri van de beroepsvereniging van gynaecologen (Nederlandse Vereniging van Obstetrie en Gynaecologie (NVOG)). Deze werkgroep van de NVOG is akkoord met het nieuwe protocol. ”
Je présenterai des mesures pour, déclare Marisol Touraine
La ministre de la Santé Marisol Touraine s’est déclarée lundi “favorable” à la mise en place d’actions de groupe (“class actions”) concernant la santé et annoncé qu’elle présenterait début 2014 un projet de loi spécifique en ce sens.
“Je suis favorable à ce qu’on mette en place des actions de groupes concernant la santé. Je présenterai des mesures en ce sens au début de l’année 2014 dans le cadre d’un projet de loi spécifique à la santé“, a-t-elle déclaré sur Canal+. “Je suis favorable à ce que dans le domaine de la santé, avec des règles particulières qui prennent en compte la spécificité du fait que ce sont notre corps et notre santé qui sont concernés, des associations puissent engager (des actions de groupe). Cela représentera une avancée démocratique majeure“, a assuré Marisol Touraine.
Medicine and the marketers – the eclipse of care – Stockholm syndrome – doctoring the data – there is a solution
This searing indictment, Dr. David Healy‘s most comprehensive and forceful argument against the pharmaceuticalization of medicine, tackles problems in health care that are leading to a growing number of deaths and disabilities. Dr. David Healy, who was the first to draw attention to the now well-publicized suicide-inducing side effects of many anti-depressants, attributes our current state of affairs to three key factors: product rather than process patents on drugs, the classification of certain drugs as prescription-only, and industry-controlled drug trials. These developments have tied the survival of pharmaceutical companies to the development of blockbuster drugs, so that they must overhype benefits and deny real hazards. Dr. David Healy further explains why these trends have basically ended the possibility of universal health care in the United States and elsewhere around the world. He concludes with suggestions for reform of our currently corrupted evidence-based medical system.
” More people are being diagnosed with cancer than ever before, and as treatment improves, more people are living longer with cancer than ever before. The number of people living with cancer in the UK is increasing by 3% every year. We know that there are currently two million people in the UK living with a cancer diagnosis, and if the current rate continues, the number will have doubled to four million people by 2030. Evidence shows that many of these cancer survivors have unmet needs, particularly at the end of treatment, whilst others are struggling with consequences of treatment, that could be either avoided or managed. ”